Corcept Therapeutics Incorporated (CORT) Stock: Price, Forecast & Analyst Target
Corcept Therapeutics Incorporated (CORT) — MoonshotScore 91/100 (Exceptional band), calculated Nov 18, 2026. Price $67.79 (-3.25%), as of the Nov 18, 2026 trading session; market cap $7.42B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 20.02× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Corcept Therapeutics Incorporated · CORT · NASDAQ · Healthcare · Medical - Pharmaceuticals
Research dated 2026-09-13: Corcept Therapeutics sells Korlym for hypercortisolism in adults with Cushing’s syndrome while developing selective cortisol modulators for endocrine and oncology uses. The equity story depends on whether Korlym can sustain expanding commercial spending and pipeline investment until relacorilant becomes a meaningful complement, while a demanding valuation already anticipates substantial growth.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Corcept Therapeutics (CORT)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and durable growth, but an expensive valuation. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Quiet.
- EPS beat 3 of the last 8 reports
- Altman Z 25.80 · Piotroski F 6
- ROE 22.1% · ROA 7.5% · current ratio 3.00
Helping: business quality, balance-sheet strength, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 86 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $67.79 | |
| Change on the day | -3.25% | |
| 52-week range | $28.66–$126.38 | |
| Market capitalisation | $7.42B | — |
| Price / earnings (trailing) | 46.71 | |
| Shares traded on the day | 744.8K | |
| Beta (volatility vs the S&P 500) | 0.45 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect our growth to continue and are reiterating our 2026 revenue guidance of $1.1 billion to $1.2 billion.
Atabak Mokari · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Corcept Therapeutics (CORT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Corcept Therapeutics (CORT), and what does it report?
Short answer · as of
Corcept is a commercial pharmaceutical company built around cortisol modulation, not a development-stage biotechnology company waiting for initial product revenue. Korlym is its primary marketed treatment, prescribed for hyperglycemia caused by hypercortisolism in eligible adults with endogenous Cushing’s syndrome when surgery has failed or is unsuitable.
Research dated 2026-09-13.
Reported revenue therefore measures principally the commercialization of Korlym, while research spending supports relacorilant and other selective cortisol modulators across endocrine and oncology indications. This combination produces the unusual reporting shape: established product revenue and profit alongside research expenditure that remains large relative to operating income.
What do the latest results show for Corcept Therapeutics (CORT)?
Research dated 2026-09-13.
The latest period reversed the preceding contraction: revenue rebounded sharply, the operating loss became a profit, and operating cash flow returned to positive territory. Research expense eased from the prior period, but selling and administrative expense continued climbing; Corcept’s exceptionally high gross margin allowed much of the revenue recovery to reach operating profit despite that heavier commercial cost base.
Recent earnings have been volatile and revenue had repeatedly fallen short of market estimates before the latest result exceeded expectations. Management subsequently raised its revenue outlook and said it expects growth to continue, but that statement is guidance rather than evidence that the latest acceleration will persist.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $340.47M Sep 30, 2026
- Latest quarter · R&D
- $56.71M Sep 30, 2026
- Latest quarter · SG&A
- $164.43M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $114.72M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $340.47M | $56.71M | $164.43M | $114.72M |
| Jun 30, 2026 | $256.15M | $53.89M | $156.90M | $41.30M |
| Mar 31, 2026 | $164.90M | $66.27M | $145.36M | −$49.60M |
| Dec 31, 2025 | $202.13M | $64.86M | $130.24M | $4.49M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $340.47M Nov 3, 2026
- Latest report · revenue estimate
- $339.13M Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $340.47M | $339.13M | $1.0100 | $0.8400 |
| Jul 29, 2026 | $256.15M | $221.15M | $0.3600 | $0.0243 |
| Apr 30, 2026 | $164.90M | $185.27M | −$0.3000 | −$0.1102 |
| Feb 24, 2026 | $202.13M | $254.94M | $0.2000 | $0.3300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $208M | $20M | $0.16 (diluted) |
| Q4 FY2025 | $202M | $24M | $0.20 (diluted) |
| Q1 FY2026 | $165M | -$32M | -$0.30 (diluted) |
| Q2 FY2026 | $256M | $43M | $0.36 (diluted) |
What are the financial strengths and risks for Corcept Therapeutics (CORT)?
Short answer
Cash and short-term investments were $370.70M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $142.89M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Corcept carries substantial cash and short-term investments, minimal debt, and liquidity ratios that indicate ample coverage of near-term obligations. The marketed business has generated annual profit and operating cash flow has usually remained positive, while capital expenditure is modest.
The cash balance nevertheless ended the reported window below its opening level. More important, current economics remain concentrated in Korlym while research and commercial expenses consume a large share of gross profit; weaker Korlym demand would therefore pressure earnings and internal pipeline funding at the same time. The market value stands far above net cash, so balance-sheet strength offers limited protection against a reassessment of expected growth.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Rich valuation — a P/E of 46.71 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $142.89M Sep 30, 2026
- Previous quarter · operating cash flow
- $33.54M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $142.89M | −$710,000 |
| Jun 30, 2026 | $33.54M | −$2.53M |
| Mar 31, 2026 | −$16.77M | −$200,000 |
| Dec 31, 2025 | $38.45M | −$50,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Corcept Therapeutics (CORT)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
At the scheduled earnings release, compare revenue with the elevated market estimate and examine whether operating profit and cash generation hold as selling and administrative spending expands. Confirmation would be continued revenue strength with positive operating cash flow; renewed revenue weakness alongside rising expenses would challenge the latest recovery.
Management’s raised outlook also needs support from reported sales rather than guidance alone. Beyond the near-term result, the widening range of longer-horizon revenue estimates shows that expectations depend heavily on how far Corcept can extend its cortisol franchise, making progress around relacorilant commercially consequential.
What management is planning
How does Corcept Therapeutics compare with its peers?
Short answer
Corcept Therapeutics's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Corcept sits between a mature specialty-drug company and a pipeline-focused biotechnology business. Korlym already supports high gross profit, annual earnings, and internal cash generation, while relacorilant and other cortisol modulators create development optionality without making the company dependent on external financing for routine operations.
That profile differs from a diversified pharmaceutical company because current commercial exposure is concentrated in Korlym and much of the pipeline remains tied to cortisol biology. It also differs from a pre-commercial peer because product demand, commercial spending, and operating cash flow already determine near-term results. Investors are therefore evaluating execution in an existing Cushing’s franchise together with the prospect of broader endocrine and oncology uses.
| Company | Price | Market value | Score |
|---|---|---|---|
| $403.60 Nov 18, 2026 | $46.1B | 96 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| Corcept Therapeutics (CORT) — this page | $67.79 | $7.42B | 91 |
| $9.01 Nov 18, 2026 | $585M | 51 5-pillar Nov 18, 2026 | |
| $22.98 Nov 18, 2026 | $1.42B | 50 5-pillar Nov 18, 2026 | |
| $247.77 Nov 18, 2026 | $15.9B | 40 5-pillar Nov 18, 2026 | |
| $2.37 Nov 18, 2026 | $211M | 36 5-pillar Nov 18, 2026 | |
| $134.00 Nov 18, 2026 | $7.05B | 34 5-pillar Nov 18, 2026 | |
| $5.94 Nov 18, 2026 | $126M | 32 5-pillar Nov 18, 2026 | |
| $0.36 Nov 18, 2026 | $30.7M | 30 5-pillar Nov 18, 2026 | |
| $0.90 Nov 18, 2026 | $20.0M | 29 5-pillar Nov 18, 2026 | |
| $19.24 Nov 18, 2026 | $133M | 22 5-pillar Nov 18, 2026 | |
| $1.61 Nov 18, 2026 | $57.9M | 21 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $165.00
- Consensus target
- $132.80
- Median target
- $150.00
Consensus record · Captured .
Measured against a quoted price of $67.79 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 55
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 25
- Other transactions
- 30
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 76.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 79.3% Prior to period end Sep 30, 2026
- Reporting holders
- 525 Period end Sep 30, 2026
- Previous quarter · holders
- 451 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 10,195,060 |
| Ingalls & Snyder LLC | 7,667,798 |
| Renaissance Technologies LLC | 4,850,083 |
| Vanguard Portfolio Management LLC | 4,777,065 |
| Vanguard Capital Management LLC | 4,353,398 |
Tracked investors
Which of the 16 named investors we follow held CORT in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.13% | $30.90M | Added +365.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Corcept Therapeutics (CORT)?
Common Questions About CORT (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Is Korlym still Corcept’s commercial engine?
Korlym remains Corcept’s primary commercial offering, so reported revenue principally reflects demand for its use in eligible adults with Cushing’s syndrome. The pipeline broadens the opportunity set but does not yet replace Korlym as the foundation of current economics.
How could relacorilant change Corcept’s business?
Relacorilant is being developed for Cushing’s syndrome and, with nab-paclitaxel, for advanced ovarian tumors. Successful commercialization could reduce reliance on Korlym and extend Corcept’s cortisol-modulation franchise into oncology.
Why did Corcept return to profit after its recent loss?
Revenue recovered sharply while research expense eased, more than offsetting continued growth in selling and administrative costs. Corcept’s very high gross margin amplified the effect of that revenue rebound on operating profit and cash flow.
Can Korlym fund Corcept’s cortisol-modulator pipeline?
The marketed business has produced annual profit and generally positive operating cash flow, while substantial liquidity and minimal debt provide additional capacity. Rising research and commercial expenses mean that continued Korlym demand remains important to preserving that self-funded model.
What is the CORT stock price today?
The last price recorded for Corcept Therapeutics Incorporated (CORT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CORT price target?
The analyst consensus price target for Corcept Therapeutics Incorporated (CORT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com